Gene expression and anemia of chronic renal failure

慢性肾衰竭的基因表达与贫血

• 批准号: 6823475
• 负责人: Saul Nurko
• 金额: $ 12.66万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-17 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6823475
• 关键词: anemia; chronic renal failure; clofibrate; cytochrome P450; drug resistance; enzyme activity; erythropoiesis; erythropoietin; gene expression; insulinlike growth factor; kidney disorder chemotherapy; laboratory mouse; liver; microarray technology; nonhuman therapy evaluation; peroxisome proliferator activated receptor; pharmacogenetics; renal failure; therapy adverse effect; tissue /cell culture

DESCRIPTION (provided by applicant): This revised application describes a rigorous training program of education and investigation to facilitate the applicant's development into an independent physician-scientist in the field of anemia of chronic renal failure (CRF). The applicant, Dr. Saul Nurko, is a nephrologist at the Cleveland Clinic, with a principal clinical interest in CRF and its consequences. Training will be supervised by the Sponsor, Dr. Paul Fox. His laboratory in the Dept. of Cell Biology investigates cellular and molecular mechanisms regulating iron homeostasis, and defects that lead to anemia. Dr. Linda Graham, project Co-Sponsor, is a vascular surgeon who will have primary responsibility for training and performance in studies using the surgical model of CRF in the mouse. Anemia is a common and debilitating consequence of advanced kidney disease. The advent of recombinant human erythropoietin (Epo) treatment significantly changed how nephrologists manage anemia in this population, and has led to better outcomes and a higher quality of life for most patients. However, the response to Epo is variable and up to 10 percent of the dialysis population are "Epo-resistant". Variations in Epo-responsiveness may be due to physiological factors including uremia, inflammation, iron status, and environmental and genetic factors. We propose to investigate the expression of genes influencing the response to Epo during CRF. We have begun a microarray-based approach to identify candidate genes with altered expression during CRF induction or after treatment with Epo. A mouse model of surgery-induced CRF was selected which gives a state of uremia and anemia comparable to human disease. In Preliminary Studies, mice were subjected to CRF for 3 wk, and then half were treated with Epo for an additional 3 wk. Systemic responses were as described previously, namely, induction of severe uremia and anemia. Treatment with Epo partially restored hematological parameters in most mice. At sacrifice, RNA was isolated from liver, spleen, and bone marrow. Liver RNA from 2 mice in each group was analyzed using the Affymetrix GeneChip system. CRF induced the expression of several peroxisome proliferator-activated receptor (PPAR)-alpha-inducible genes including cytochrome p450 type A10 and insulin-like growth factor binding protein (IGFBP)-1. To our knowledge this is the first evidence for activation of hepatic PPAR-alpha by CRF. Our preliminary studies have led us to propose the following hypothesis: Activation of liver PPAR-alpha during CRF, possibly via uremic toxins in blood, alters the expression of specific hepatic genes. Dysregulation of these genes inhibits erythropoiesis, particularly, in response to Epo. We will test this hypothesis by pursuing the following Specific Aims: (1) Determine the effects of CRF on the expression of PPAR-(-induced and erythropoiesis-related genes in liver (2) determine the relationship between the extent of CRF and PPAR-alpha activity and erythropoiesis in mice with CRF, and (3) determine the in vivo role of PPAR-alpha in CRF-mediated alteration of gene expression using PPAR-alpha-null and clofibrate-treated mice. We expect that these studies will help us to understand the molecular mechanisms involved in Epo-resistance during CRF, and possibly will lead to the development of therapeutic agents that overcome this resistance and potentiate the activity of Epo.

描述（由申请人提供）： 本修订申请描述了严格的教育和调查培训计划，以促进申请人发展成为慢性肾衰竭贫血（CRF）领域的独立医生-科学家。申请人扫罗·努尔科博士是克利夫兰诊所的肾病学家，主要临床兴趣是CRF及其后果。培训将由申办者Paul Fox博士监督。他在系里的实验室。细胞生物学研究调节铁稳态的细胞和分子机制，以及导致贫血的缺陷。项目共同申办者琳达格雷厄姆博士是一名血管外科医生，主要负责使用小鼠CRF手术模型进行研究的培训和性能。 贫血是晚期肾脏疾病的常见和衰弱的后果。重组人促红细胞生成素（Epo）治疗的出现显着改变了肾脏病学家在这一人群中管理贫血的方式，并为大多数患者带来了更好的结局和更高的生活质量。然而，对Epo的反应是可变的，高达10%的透析人群是“Epo耐药”的。Epo反应性的变化可能是由于生理因素，包括尿毒症、炎症、铁状态以及环境和遗传因素。我们建议调查基因的表达影响反应促红细胞生成素在CRF。我们已经开始了一个基于微阵列的方法，以确定候选基因与CRF诱导或治疗后的表达改变与促红细胞生成素。选择手术诱导的CRF的小鼠模型，其提供与人类疾病相当的尿毒症和贫血状态。在初步研究中，小鼠接受CRF 3周，然后一半用Epo治疗另外3周。全身反应如前所述，即诱导重度尿毒症和贫血。Epo治疗部分恢复了大多数小鼠的血液学参数。处死时，从肝脏、脾脏和骨髓中分离RNA。使用Affyssin GeneChip系统分析来自每组中2只小鼠的肝RNA。CRF诱导了几种过氧化物酶体增殖物激活受体（PPAR）-α诱导基因的表达，包括细胞色素p450 A10型和胰岛素样生长因子结合蛋白（IGFBP）-1。据我们所知，这是CRF激活肝脏PPAR-alpha的第一个证据。我们的初步研究使我们提出了以下假设：CRF期间肝脏PPAR-alpha的激活，可能通过血液中的尿毒症毒素，改变了特定肝脏基因的表达。这些基因的失调抑制红细胞生成，特别是对Epo的反应。我们将通过追求以下具体目标来检验这一假设：（1）测定CRF对PPAR-γ表达的影响。（2）确定CRF程度和PPAR-alpha活性与CRF小鼠红细胞生成之间的关系，和（3）使用PPAR-alpha-null和氯贝酯处理的小鼠确定PPAR-alpha在CRF介导的基因表达改变中的体内作用。我们期望这些研究将有助于我们了解CRF期间Epo耐药的分子机制，并可能导致开发克服这种耐药并增强Epo活性的治疗剂。